Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO1990006109) ADHERENCES DE MYCOPLASMA PNEUMONIAE ET DE MYCOPLASMA HOMINUS A DU SULFATURE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:

1. A receptor for pathogens selected from the group consisting of M. hominus and M. pneumoniae comprising a compound selected from the group consisting of dextran sulfate and compounds containing the structure

SO3-Galβ1-1Ceramide.
2. A receptor according to claim 1 wherein said compound containing the structure SO3-Galβ1-1Ceramide is selected from the group consisting of sulfatides and sialyloligosaccharides.
3. A pharmaceutical composition comprising the receptor according to claim 1 in a pharmaceutically acceptable carrier.
4. The composition according to claim 3 wherein said pharmaceutically acceptable carrier is soluble in water.
5. The composition according to claim 3 wherein said pharmaceutically acceptable carrier is insoluble in water.
6. A method for removing a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae from a sample, comprising contacting said sample with a receptor according to claim 1, incubating said sample with said receptor for a sufficient period of time to bind said sample to said receptor, and removing said receptor from said sample.
7. The method according to claim 6 wherein said receptor is carried on a solid, water-insoluble carrier.
8. A method for treating a patient infected with, a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae comprising administering to said patient an effective amount of a composition according to claim 3.

9. A method for detecting a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising:
immobilizing fetuin onto a suitable carrier;
contacting a sample to be analyzed with the immobilized fetuin;
and detecting the presence of the pathogen using an enzyme-dextran sulfate conjugate.
10. A method of preventing infection in a host by a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising administering to a host an effective amount of a composition according to claim 3.
11. A method for treating diseased tissue which is infected with a pathogen selected from the group consisting of Mycoplasma pneumoniae and Mycoplasma hominus comprising contacting said diseased tissue with a composition according to claim 3.

AMENDED CLAIMS
[received by the International Bureau
on 20 April 1990 (20.04.90);
original claims 1-3, 6 and 7 amended;
other claims unchanged (1 page)]

1. A receptor analog for pathogens selected from the group consisting of M. hominus and M. pneumoniae comprising a compound selected from the group consisting of dextran sulfate and compounds containing the structure SO3-GalB1-1-Ceramide.
2. A receptor analog according to claim 1 wherein said compound containing the structure S03-GalB1-1-Ceramide is selected from the group consisting of sulfatides and sialyloligosaccharides.
3. A pharmaceutical composition comprising the receptor analog according to claim 1 in a pharmaceutically acceptable carrier.
4. The composition according to claim 3 wherein said pharmaceutically acceptable carrier is soluble in water.
5. The composition according to claim 3 wherein said pharmaceutically acceptable carrier is insoluble in water.
6. A method for removing a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae from a sample, comprising contacting said sample with a receptor analog according to claim 1, incubating said sample with said receptor for a sufficient period of time to bind said sample to said receptor, and removing said receptor from said sample.
7. The method according to claim 6 wherein said receptor analog is carried on a solid, water-insoluble carrier.
8. A method for treating a patient infected with a pathogen selected from the group consisting of Mycoplasma hominus and Mycoplasma pneumoniae comprising administering to said patient an effective amount of a composition according to claim 3.

STATEMENT UNDER ARTICLE 19

Claims 1-3, 6 and 7 have been amended to more particularly point out the nature of the receptor of this invention. The amendments are not considered to have any impact on the description.